Substituted naphthalene compounds as calcium sensing receptor modulators

摘要

The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

主权项

1. A compound having the Formula (I): ring A is phenyl or naphthyl; R1 is hydrogen or substituted or unsubstituted (C1-C6)alkyl; R2, which may be same or different at each occurrence, is independently selected from halogen, cyano, substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C1-C6)haloalkyl, substituted or unsubstituted (C1-C6)hydroxyalkyl, —X—C(O)—Z, —OR9, —NR7R8, —NR7C(O)R6, —S(O)0-2R6, —S(O)2NR7R8, —NR7S(O)2R6, substituted or unsubstituted (C3-C12)cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted 5- to 6-membered heteroaryl, substituted or unsubstituted 5- to 6-membered heterocyclyl and ring D; ring D is X is selected from a bond, —(CRaRb)m—, —NR2—, —O(CRaRb)m—, —(CRaRb)mO—, —C(O)NR12—, —(CRaRb)mO—(CRaRb)m— and —C(O)NR12(CRaRb)m—; Ra and Rb which may be same or different at each occurrence, are independently selected from hydrogen, halogen, hydroxy, substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C1-C6)haloalkyl and substituted or unsubstituted (C3-C6)cycloalkyl; or Ra and Rb, together with the carbon atom to which they are attached, form a substituted or unsubstituted 3 to 6 membered saturated carbocyclic ring; Z is —OR10 or —NR7R8; R3 is selected from hydrogen, halogen, substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C1-C6)haloalkyl, —OR9, and substituted or unsubstituted (C3-C12)cycloalkyl; R4, which may be same or different at each occurrence, is independently selected from halogen, substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C1-C6)haloalkyl, substituted or unsubstituted (C1-C6)alkoxyalkyl, —SF5 and —OR9; R5 is substituted or unsubstituted (C1-C6)alkyl; R6 is selected from substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C3-C12)cycloalkyl and substituted or unsubstituted (C6-C14)aryl; R7 and R8, which may be same or different at each occurrence, are independently selected from hydrogen, substituted or unsubstituted (C1-C6)alkyl, —(CRaRb)1-2R11, —(CRcRd)m—OH and substituted or unsubstituted (C3-C12)cycloalkyl; Rc and Rd which may be same or different at each occurrence, are independently hydrogen or substituted or unsubstituted (C1-C6)alkyl; R9 is independently selected from hydrogen, substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C1-C6)haloalkyl, substituted or unsubstituted (C1-C6)alkoxyalkyl and substituted or unsubstituted (C3-C12)cycloalkyl; R10 is selected from hydrogen, substituted or unsubstituted (C1-C6)alkyl and —(CRaRb)1-2phenyl; R11 is substituted or unsubstituted phenyl, wherein the substituents are selected from halogen, (C1-C6)alkyl and —OR9; R12 is hydrogen or substituted or unsubstituted (C1-C6)alkyl; ‘m’ is an integer ranging from 1 to 3, both inclusive; ‘n’ is an integer ranging from 1 to 3, both inclusive; ‘p’ is an integer ranging from 0 to 3, both inclusive; and ‘q’ is an integer ranging from 1 to 3, both inclusive; or a pharmaceutically acceptable salt thereof.